AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Tipranks

Published November 5, 2026

Psychedelic: Compass Pathways beats Q3 loss estimate - TipRanks.com

Read the full story at Tipranks

In this week's “ Psychedelic ,” The Fly's recurring series focused on psychedelic stock news, The Fly looks back on earnings, an extraction.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Psychedelic biotech